Skip to main content

Security report for anavotx.com

Anavo Therapeutics · Healthcare · United States

Medium risk. 3 critical or high findings in Security headers and SSL/TLS.

Security score

73/100

Risk levelMedium

0–100, higher is better. How it is calculated

Anavo Therapeutics is a pioneering biopharmaceutical company focused on drug discovery targeting phosphatases, a previously undruggable target class. Utilizing their proprietary IGNITE platform, they develop allosteric modulators for therapeutic programs in autoimmune diseases and cancer. The company is supported by reputable international investors and led by an experienced management team with strong scientific advisory backing. The website reflects a professional and consistent brand image with clear business focus and investor transparency. Technically, the website is built on the Squarespace platform with embedded Vimeo videos and uses modern web fonts and scripts. It is mobile optimized and performs moderately well, though accessibility features could be improved. Security posture is strong with HTTPS and HSTS enabled, and a cookie consent mechanism is in place, indicating GDPR awareness. However, the absence of a public WHOIS record, privacy policy, terms of service, and explicit contact information reduces transparency and trust. Overall, the site presents a credible and professional front for a biotech startup but would benefit from enhanced privacy and security disclosures, contact details, and domain registration transparency to improve trust and compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
95/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching anavotx.com

This scan found 22 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
35
Email security
70
DNS health
75
Network security
100
GDPR outside view
95
Average
73

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Anavo Therapeutics occupies a niche market position as the first company systematically targeting phosphatases for drug discovery, addressing a significant unmet need in the biopharmaceutical industry. Their business model combines proprietary platform development with therapeutic program advancement and partnership support. The company targets investors, partners, and biotech professionals, leveraging a strong advisory board and blue-chip investors to establish credibility. Growth indicators include recent funding rounds and a focus on autoimmune and oncology indications. The partnership ecosystem includes major venture capital and pharmaceutical investors, enhancing strategic positioning. The company’s operations appear focused on innovation and pipeline development rather than direct sales or e-commerce. The website content and structure support investor relations and recruitment efforts, indicating a growth and talent acquisition phase.

Security posture

The website demonstrates a mature security posture with enforced HTTPS and HSTS headers, reducing risks of man-in-the-middle attacks. The presence of a cookie consent banner aligns with GDPR requirements, though no explicit privacy policy or terms of service documents were found, representing a compliance gap. No security.txt or vulnerability disclosure information is published, limiting transparency for security researchers. No exposed sensitive data or vulnerable libraries were detected in the site scripts. The absence of contact information for incident response or security inquiries is a weakness. Overall, the security posture is good but could be improved by publishing comprehensive policies and contact channels.

Recommendations

  1. Publish a comprehensive privacy policy and terms of service to improve legal compliance and user trust.
  2. Provide clear contact information including company email and phone numbers for general and security inquiries.
  3. Implement and publish a security.txt file to facilitate responsible vulnerability disclosure.
  4. Enhance website accessibility features to meet WCAG standards and improve user experience for all visitors.
  5. Increase transparency of domain registration information or use verified WHOIS records to strengthen legitimacy.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Anavo Therapeutics
Description
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. They develop first-in-class therapeutic programs targeting phosphatases using their IGNITE platform, focusing on autoimmune diseases and cancer. Backed by blue-chip investors, they aim to unlock the therapeutic potential of phosphatase-targeted allosteric modulators.
Key services
Phosphatase drug discovery, Development of allosteric modulators, Therapeutic programs in autoimmune diseases and cancer, Partnership support for pipeline development
Content quality
good
Branding
consistent

Technology

Stack
Squarespace CMS, Vimeo video embedding, Typekit fonts, JavaScript libraries (Squarespace scripts)
Platforms
Squarespace
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • HSTS enabled
  • Cookie consent banner implemented

Analytics and tracking

Tracking level
minimal
Privacy practices
basic

Advertising

Transparency
poor

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and content-rich for a biotech startup.
  2. No public WHOIS data reduces transparency.
  3. No explicit privacy policy or terms of service found.
  4. Cookie consent banner is implemented indicating GDPR awareness.
  5. No contact emails or phone numbers explicitly listed on the homepage.
  6. Social media presence on LinkedIn and Twitter is active and linked.
  7. No security.txt or vulnerability disclosure information found.
  8. No visible forms for contact or data collection on the homepage.
  9. Website uses Squarespace platform with embedded Vimeo videos.
  10. No advertising or tracking scripts detected beyond platform defaults.
Technical notes

Notes

The website is built on the Squarespace CMS platform, leveraging its built-in content management and hosting capabilities. It uses embedded Vimeo videos for rich media content and Typekit fonts for typography. The site loads multiple compressed JavaScript bundles from Squarespace, indicating a modern but platform-dependent tech stack. Performance is moderate, with good mobile optimization and responsive design. SEO is supported by proper meta tags and Open Graph data. Accessibility is basic and could be improved. The site lacks custom analytics or tracking scripts beyond platform defaults, indicating minimal user tracking. Overall, the technical infrastructure is solid for a startup but limited in customization and advanced features.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with anavotx.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review anavotx.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.